Key facts
- It has raised $17.0M; the latest was Later Stage VC in Jun 2025.
- Notable investors include Edward Schutter, Erik Selin, M2 Asset Management, Rutger Arnhult.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Intrance Medical Systems
- ·The full record, as it builds
Funding rounds
No funding rounds for Intrance Medical Systems are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Intrance Medical Systems
Operator of a biopharmaceutical company intended to develop and commercialize treatments for advanced Parkinson's disease. The company develops a triple-drug gel formulation that modifies the metabolism of levodopa, reducing peripheral side effects and increasing its effectiveness in the brain via a wearable, lightweight infusion pump that administers the medication directly into the small intestine, ensuring consistent delivery and minimizing gastrointestinal issues, enabling patients with advanced Parkinson's disease to improve the quality of life and maintain greater independence and control over their symptoms.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2018
- Employees
- 4
- Website
- intrancemedical.com/
- Ownership
- Privately Held (backing)
Intrance Medical Systems doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Intrance Medical Systems shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Intrance Medical Systems in its N-PORT filings yet. We sweep new filings monthly.